The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: A report on 241 cases

Blood

Volumn 111, Issue 10, 2008, Pages 4922-4929

  Kiladjian, Jean Jacques ^a,j   Cervantes, Francisco ^b   Leebeek, Franck W G ^c   Marzac, Christophe ^d   Cassinat, Bruno ^e   Chevret, Sylvie ^e   Cazals Hatem, Dominique ^f   Plessier, Aurélie ^f   Garcia Pagan, Juan Carlos ^g   Murad, Sarwa Darwish ^c   Raffa, Sebastian ^g   Janssen, Harry L A ^c   Gardin, Claude ^a   Cereja, Sophie ^a   Tonetti, Carole ^h   Giraudier, Stéphane ^h   Condat, Bertrand ^f   Casadevall, Nicole ^d,i   Fenaux, Pierre ^a   Valla, Dominique C ^f  

^a UNIVERSITÉ PARIS 13   (France)

^b UNIVERSITY OF BARCELONA   (Spain)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d HÔPITAL SAINT ANTOINE   (France)

^e SAINT LOUIS HOSPITAL   (France)

^f BEAUJON HOSPITAL   (France)

^g INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^h HENRI MONDOR HOSPITAL   (France)

ⁱ INSTITUT GUSTAVE ROUSSY   (France)

^j AVICENNE HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; THROMBOPOIETIN RECEPTOR; MPL PROTEIN, HUMAN;

ADULT; ARTICLE; BONE MARROW; BUDD CHIARI SYNDROME; CONTROLLED STUDY; EEC SYNDROME; EXON; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PORTAL VEIN THROMBOSIS; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; SPLANCHNIC NERVE; SURVIVAL TIME; VEIN THROMBOSIS; BONE MARROW EXAMINATION; GENETICS; MIDDLE AGED; MORTALITY; MUTATION; MYELOPROLIFERATIVE DISORDER; RETROSPECTIVE STUDY; SPLANCHNIC BLOOD FLOW;

ADULT; BONE MARROW EXAMINATION; BUDD-CHIARI SYNDROME; FEMALE; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; MYELOPROLIFERATIVE DISORDERS; PROGNOSIS; RECEPTORS, THROMBOPOIETIN; RETROSPECTIVE STUDIES; SPLANCHNIC CIRCULATION; VENOUS THROMBOSIS;

EID: 46749132374     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-11-125328     Document Type: Article

References (45)

1. Gruppo Italiano Studio Policitemia. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med. 1995;123:656-664.
2. De Stefano V, Teofili L Leone G, Michiels JJ. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis. Semin Thromb Hemost. 1997;23:411-418.
3. Janssen HL, Garcia-Pagan JC, Elias E, Mentha G, Hadengue A, Valla DC. Budd-Chiari syndrome: a review by an expert panel. J Hepatol. 2003;38:364-371.
4. Chung RT, lafrate AJ, Amrein PC, Sahani DV, Misdraji J. Gase records of the Massachusetts General Hospital. Case 15-2006: a 46-year-old woman with sudden onset of abdominal distention. N Engl J Med. 2006;354:2166-2175.
5. Menon KV, Shah V, Kamath PS. The Budd-Chiari syndrome. N Engl J Med. 2004;350:578-585.
6. Valla D, Casadevall N, Huisse MG, et al. Etiology of portal vein thrombosis in adults: a prospective evaluation of primary myeloproliferative disorders. Gastroenterology. 1988;94:1063-1069.
7. Valla D, Casadevall N, Lacombe C, et al. Primary myeloproliferative disorder and hepatic vein thrombosis: a prospective study of erythroid colony formation in vitro in 20 patients with Budd- Chiari syndrome. Ann Intern Med. 1985;103:329- 334.
8. Chait Y, Condat B, Cazals-Hatem D, et al. Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis. Br J Haematol. 2005; 129:553-560.
9. Michiels JJ, Thiele J. Clinical and pathologic criteria tor the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia). Int J Hematol. 2002;76:133-145.
10. Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood. 2002;100:4272- 4290.
11. Westwood NB, Pearson TC. Diagnostic applications of haemopoietic progenitor culture techniques in polycythaemias and thrombocythaemias. Leuk Lymphoma. 1996;22(Suppl 1):95- 103.
12. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365: 1054-1061.
13. James C, Ugo V, Le Couedic JP et al. Aunique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005: 434:1144-1148.
14. Kralovics R, Passamonti F, Buser AS, et al. Again-of- function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-1790.
15. Levine RL, Wadleigh M, Gools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005:7:387-397.
16. Patel RK, Lea NC, Heneghan MA, et al. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology. 2006;130:2031 -2038.
17. Smalberg JH, Murad SD, Braakman E, Valk PJ, Janssen HL. Leebeek FW. Myeloproliferative disease in the pathogenesis and survival of Budd-Chiari syndrome. Haematologica. 2006;91:1712-1713.
18. Spivak JL Moliterno AR, Silver RT. Case 15-2006: the Budd-Chiari syndrome and V617F mutation in JAK2. N Engl J Med. 2006;355:737; author reply 738.
19. Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006; 108:3472-3476.
20. Pikman Y. Lee BH. Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006; 3:e270.
21. Scott LM. Beer PA, Bench AJ, Erber WN, Green AR. Prevalence of JAK2 V617F and exon 12 mutations in polycythaemia vera. Br J Haematol. 2007;139:511-512.
22. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356:459-468.
23. Condat B, Pessione F, Hillaire S, et al. Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy. Gastroenterology. 2001;120:490-497.
24. Thiele J, Kvasnicka HM, Orazi A. Bone marrow histopathology in myeloproliferative disorders: current diagnostic approach. Semin Hematol. 2005;42:184-195.
25. James C, Delhommeau F, Marzac G, et al. Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis. Leukemia. 2006;20:350- 353.
26. Kiladjian JJ, Cassinat B, Turlure P, et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood. 2006;108:2037-2040.
27. Chaligne R, James C, Tonetti C, et al. Evidence for MPLW515L/K mutations in hematopoietic stem cells in primitive myelofibrosis. Blood. 2007; 110:3735-3743.
28. Pugh RN, Murray-Lyon IM, Dawson JL Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646-649.
29. Murad SD, Valla DC, de Groen PC, et al. Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. Hepatology. 2004:39:500-508.
30. Zeitoun G, Escolano S, Hadengue A, et al. Outcome of Budd-Chiari syndrome: a multivariate analysis of factors related to survival including surgical portosystemic shunting. Hepatology. 1999;30:84-89.
31. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of- care diagnostic algorithms. Leukemia. 2008;22: 14-22.
32. Primignani M, Barosi G, Bergamaschi G, et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology. 2006;44:1528- 1534.
33. Colaizzo D. Amitrano L, Tiscia GL, et al. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost. 2007;5:55-61.
34. Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23: 2224-2232.
35. McMullin MF, Bareford D, Campbell P, et al. Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br J Haematol. 2005;130:174-195.
36. Dobo I Donnard M, Girodon R et al. Standardization and comparison of endogenous erythroid colony assays performed with bone marrow or blood progenitors for the diagnosis of polycythemia vera. Hematol J 2004;5:161-167.
37. Colaizzo D. Amitrano L, Tiscia GL, Grandone E, Guardascione MA, Margaglione M. A new JAK2 gene mutation in patients with polycythemia vera and splanchnic vein thrombosis. Blood. 2007; 110: 2768-2769.
38. Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med. 2006;355:2452-2466.
39. Dupont S, Masse A, James C, et al. The JAK2 617V>R mutation triggers erythropoietin hyper-sensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood. 2007;110:1013-1021.
40. Scott LM, Scott MA, Gampbell PJ, Green AR. Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood. 2006; 108:2435-2437.
41. Passamonti F, Rumi E, Pietra D, et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood. 2006;107:3676-3682.
42. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood. 2007;110:840- 846.
43. Boissinot M, Lippert E, Girodon F. et al. Latent myeloproliferative disorder revealed by the JAK2- V617F mutation and endogenous megakaryocytc colonies in patients with splanchnic vein thrombosis. Blood. 2006;108:3223-3224.
44. Denninger MH, Chait Y, Casadevall N, et al. Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology. 2000;31:587-591.
45. Plessier A, Sibert A. Consigny Y, et al. Aiming at minimal invasiveness as a therapeutic strategy for Budd-Chiari syndrome. Hepatology. 2006;44: 1308-1316.